FDA Appoints Long‑time Agency Veteran to Lead Drug Division

Richard Pazdur Takes the Helm Amidst Organizational Challenges

Dr. Richard Pazdur, who has served as the FDA’s chief regulator for oncology medicines, has been named the new head of the agency’s Drug Division. His appointment is seen as a stabilizing move for an organization currently grappling with significant staff reductions and waning morale.

Having overseen the approval and monitoring of countless cancer therapies, Dr. Pazdur brings a depth of experience that many analysts believe will help steer the division through a period of uncertainty. “Continuity and expertise are exactly what the FDA needs right now,” said a senior industry observer.

The decision comes at a time when the agency is under pressure to maintain rigorous drug‑safety standards while contending with budget constraints and a shrinking workforce. By selecting a proven leader from within, the FDA aims to reinforce confidence among stakeholders and ensure that critical drug‑evaluation processes remain robust.